Rapid-Release Griffithsin Fibers for Dual Prevention of HSV-2 and HIV-1 Infections
- 1 June 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (6)
- https://doi.org/10.1128/AAC.02139-19
Abstract
The biologic griffithsin (GRFT) has recently emerged as a candidate to safely prevent sexually transmitted infections (STIs), including human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus 2 (HSV-2). However, to date, there are few delivery platforms that are available to effectively deliver biologics to the female reproductive tract (FRT). The goal of this work was to evaluate rapid-release polyethylene oxide (PEO), polyvinyl alcohol (PVA), and polyvinylpyrrolidone (PVP) fibers that incorporate GRFT in in vitro (HIV-1 and HSV-2) and in vivo (HSV-2) infection models. GRFT loading was determined via enzyme-linked immunosorbent assay (ELISA), and the bioactivity of GRFT fibers was assessed using in vitro HIV-1 pseudovirus and HSV-2 plaque assays. Afterwards, the efficacy of GRFT fibers was assessed in a murine model of lethal HSV-2 infection. Finally, murine reproductive tracts and vaginal lavage samples were evaluated for histology and cytokine expression, 24 and 72 h after fiber administration, to determine safety. All rapid-release formulations achieved high levels of GRFT incorporation and were completely efficacious against in vitro HIV-1 and HSV-2 infections. Importantly, all rapid-release GRFT fibers provided potent protection in a murine model of HSV-2 infection. Moreover, histology and cytokine levels, evaluated from collected murine reproductive tissues and vaginal lavage samples treated with blank fibers, showed no increased cytokine production or histological aberrations, demonstrating the preliminary safety of rapid-release GRFT fibers in vaginal tissue.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (U19-AI113182)
- HHS | NIH | National Institute of General Medical Sciences (P20-GM125504)
This publication has 71 references indexed in Scilit:
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cellsVirology, 2012
- Griffithsin Has Antiviral Activity against Hepatitis C VirusAntimicrobial Agents and Chemotherapy, 2011
- Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?Clinical Infectious Diseases, 2011
- Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide CandidatePLOS ONE, 2011
- Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family CoronaviridaeJournal of Virology, 2010
- Silk nanospheres and microspheres from silk/pva blend films for drug deliveryBiomaterials, 2010
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentProceedings of the National Academy of Sciences of the United States of America, 2009
- Preparation and characterization of polyvinyl alcohol-gelatin hydrogel membranes for biomedical applicationsAAPS PharmSciTech, 2007